[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-system-and-related-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-system-and-related-disorders":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,78,111,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100462841","an-exploratory-study-of-arginine-supplementation-and-the-postoperative-immune-response-100462841",false,"NCT05306925","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse (ASPIRE)","ASPIRE","Inclusion Criteria:\n\n* Preterm infants born \\\u003C30 weeks gestation requiring laparotomy\u002Fmajor bowel surgery or diagnosed with necrotising enterocolitis (Modified Bell's Stage II or higher) before discharge\n* Term and near term infants (born\\>35 weeks gestation) requiring laparotomy\u002Fmajor bowel surgery in the first 3 days of life (gastroschisis; major bowel atresias expected to require at least 7 days of PN)\n\nExclusion Criteria:\n\n* Infants who are unlikely to survive because of poor immediate postoperative condition\n* Infants known (or suspected to have) a diagnosis of inborn error of metabolism or serious liver dysfunction\n* Parents who are unable to give informed consent","ALL","22 Weeks","44 Weeks",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","ASPIRE is a nutrition study focusing on the effect of arginine supplementation on immune function in postoperative infants.\n\nThe investigators will explore the effect of current intravenous feeding (parenteral nutrition (PN)) formulations and oral arginine supplementation on blood arginine levels and the genes that are involved in body nutrition and fighting infection in babies who have had major bowel surgery or been diagnosed with necrotising enterocolitis. The investigators will undertake an exploratory physiological study across two sites under which are part of a single neonatal partnership. 48 infants will be recruited; 24 preterm infants and 24 term\u002Fnear term infants. 16 of these infants (8 preterm and 8 term\u002Fnear term) will be supplemented with arginine in both oral and parenteral form, 16 infants will receive arginine supplementation in oral form alone and 16 infants will receive standard nutrition with no arginine supplement. The investigators will record nutritional intake and routine biochemical testing data (which includes amino acid levels) collected over the first 30 days post surgery or post NEC diagnosis. The investigators will take blood for analysis at prespecified intervals for RNA sequencing, ammonia and metabolomics. RNA sequencing findings will allow the investigators to describe the effect of arginine on gene activity in postoperative infants\n\nThe investigators hypothesise that arginine supplementation will result in changes in gene expression that are consistent with changes in T-cell function and associated inflammatory pathways.",[28,29,30,31],"Preterm","Surgery","Nutritional Deficiency","Immune System and Related Disorders",[33,34,35,36,37],"Neonate","Arginine","Postoperative","Immune function","Nutrition","RECRUITING","2026-02-17",{"date":41,"type":42},"2026-02-18","ACTUAL",{"date":44,"type":42},"2022-04-14",{"date":46,"type":22},"2026-12-31",{"name":48,"class":49},"University of Liverpool","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100587637","tracing-of-real-time-glu13cose-metabolism-in-human-immune-cells-100587637","NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells","TORCH","Inclusion Criteria:\n\n* Adults aged 18 or older\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner or in police custody\n* Uncontrolled hyperglycemia\u002Fdiabetes\n* Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period\n* Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives\n* Any reason which, in the opinion of the study investigator, adds additional risk to the participant",true,"18 Years",{"count":61,"type":22},12,[25],"The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.",[65,66,67,31],"Glucose","Metabolism","Isotope Labeling","2025-11-01",{"date":70,"type":42},"2025-11-04",{"date":72,"type":42},"2025-10-01",{"date":74,"type":22},"2027-06-30",{"name":76,"class":49},"Vanderbilt University Medical Center",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":58,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":50},"100546112","sand-play---the-effect-of-biodiversity-exposure-on-atopic-dermatitis-100546112","NCT06390696","Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis","Biodiversity Interventions for Well-being - the Effect of Biodiversity Exposure on Atopic Dermatitis","BIWE","Inclusion Criteria:\n\n* Eczema Area and Severity Index ≥ 2\n\nExclusion Criteria:\n\n* Eczema Area and Severity Index \\\u003C 2\n* Immune deficiencies, i.e., antibody deficiency\n* Immunosuppressive systematic medications\n* A disease affecting immune response (e.g., colitis ulcerosa, rheumatoid arthritis, Crohn's disease, diabetes)\n* Cancer diagnosis\n* Topical medication for the treatment of atopic dermatitis during the trial\n* Disability affecting the immune response (e.g. Down's syndrome)\n* Non-participation in the national vaccine program\n* Participation in another intervention or follow-up study","2 Years","5 Years",{"count":89,"type":22},80,[25],"The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood.\n\nSand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis will investigate whether the exposure to microbial diversity in sandbox reduces the symptoms of atopic dermatitis, alters commensal microbiota and modifies immune regulation in children.",[93,94,95,31],"Atopic Dermatitis","Nature, Human","Microbial Colonization",[97,98,99,100],"Atopy","Biodiversity","Commensal microbiota","Microbial exposure","2024-04-25",{"date":103,"type":42},"2024-04-30",{"date":105,"type":42},"2023-05-26",{"date":107,"type":22},"2027-09-30",{"name":109,"class":110},"Natural Resources Institute Finland","OTHER_GOV",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":77},"100429427","covid-2019-vaccine-immune-response-base-on-single-cell-multi-omics-100429427","NCT04871932","COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics","Evolution of Immune System in Healthy Adults After Vaccination of New Coronavirus (COVID-2019) Inactivated Vaccine Based on Single Cell Multi-Omics Technologies","Inclusion Criteria:\n\n1\\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease.\n\nExclusion Criteria:\n\n1\\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs","50 Years",{"count":120,"type":22},50,"OBSERVATIONAL","In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell heterogeneity in multicellular organisms. Analyzing the changes in the expression profile of the cell transcriptome at the single-cell level can clearly show the changes in the trajectory of individual cells, reveal new cell types, and discover the potential functions of immune cells. Therefore, this study intends to recruit healthy adults and use multi-omics techniques such as single-cell sequencing to systematically classify the peripheral blood mononuclear cells of healthy adults to provide a basis for further disease-related research.",[31],[125,126,127,128],"Cohort study","Immune System","PBMC","China","2021-05-29",{"date":131,"type":42},"2021-06-03",{"date":133,"type":42},"2021-02-01",{"date":135,"type":22},"2026-12-03",{"name":137,"class":49},"RenJi Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100416798","microenvironment-and-immunity-of-digestive-cancers---east-paris-multicentric-cohort-100416798","NCT04707365","Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort","Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment","MICADO","Inclusion Criteria:\n\n* Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma\n* Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment\n* Age ≥ 18 years old\n* Diagnosed from 2015 onwards\n* Signed Consent\n* Affiliation to a social security scheme (including CMU (Universal health coverage))\n\nExclusion Criteria:\n\n* Patient under guardianship, curatorship or safeguarding of justice\n* Pregnant or breastfeeding woman\n* Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.\n* Refusal to participate in the study\n* Patient on AME (state medical assistance)\n* Persons deprived of liberty by a judicial or administrative decision\n* Persons under psychiatric care",{"count":147,"type":22},200,[25],"Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies.\n\nTumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored.\n\nObjective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers.\n\nMethod: Retrospective and prospective monocentric cohort study",[151,152,153,31],"Colorectal Cancer","Pancreas Tumor","Biliary Tract Tumor","NOT_YET_RECRUITING","2021-01-12",{"date":157,"type":42},"2021-01-13",{"date":159,"type":22},"2021-03",{"date":161,"type":22},"2035-03",{"name":163,"class":49},"Assistance Publique - Hôpitaux de Paris"]